Report error Found 246 Enz. Inhib. hit(s) with all data for entry = 12453
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataKd: 1nMAssay Description:Table A2: In vivo biotinylated PRMT5-MEP50 was diluted to 4.5 μM in 25 mM Bicine pH 7.6, 100 mM NaCl, 1 mM TCEP, and 0.05% Tween-20 and injected at 5...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataKd: 1nMAssay Description:Table A2: In vivo biotinylated PRMT5-MEP50 was diluted to 4.5 μM in 25 mM Bicine pH 7.6, 100 mM NaCl, 1 mM TCEP, and 0.05% Tween-20 and injected at 5...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataKd: 1nMAssay Description:Table A2: In vivo biotinylated PRMT5-MEP50 was diluted to 4.5 μM in 25 mM Bicine pH 7.6, 100 mM NaCl, 1 mM TCEP, and 0.05% Tween-20 and injected at 5...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataKd: 1nMAssay Description:Table A2: In vivo biotinylated PRMT5-MEP50 was diluted to 4.5 μM in 25 mM Bicine pH 7.6, 100 mM NaCl, 1 mM TCEP, and 0.05% Tween-20 and injected at 5...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 1.72nMAssay Description:Table B1: The assay uses purified human, PRMT5 enzyme to convert S-adenosyl-L-[methyl-3H]methionine plus histone H4 L-arginine to S-adenosyl-L-homocy...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataKd: 2nMAssay Description:Table A2: In vivo biotinylated PRMT5-MEP50 was diluted to 4.5 μM in 25 mM Bicine pH 7.6, 100 mM NaCl, 1 mM TCEP, and 0.05% Tween-20 and injected at 5...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataKd: 2nMAssay Description:Table A2: In vivo biotinylated PRMT5-MEP50 was diluted to 4.5 μM in 25 mM Bicine pH 7.6, 100 mM NaCl, 1 mM TCEP, and 0.05% Tween-20 and injected at 5...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataKd: 2nMAssay Description:Table A2: In vivo biotinylated PRMT5-MEP50 was diluted to 4.5 μM in 25 mM Bicine pH 7.6, 100 mM NaCl, 1 mM TCEP, and 0.05% Tween-20 and injected at 5...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 2nMAssay Description:Table A1: A recombinant human dual expressed Avi PRMT5/His-MEP50) protein (corresponding to amino acids for PRMT5 2-637, and 2-342 for MEP50 expresse...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 3nMAssay Description:Table A1: A recombinant human dual expressed Avi PRMT5/His-MEP50) protein (corresponding to amino acids for PRMT5 2-637, and 2-342 for MEP50 expresse...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataKd: 5nMAssay Description:Table A2: In vivo biotinylated PRMT5-MEP50 was diluted to 4.5 μM in 25 mM Bicine pH 7.6, 100 mM NaCl, 1 mM TCEP, and 0.05% Tween-20 and injected at 5...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataKd: 6nMAssay Description:Table A2: In vivo biotinylated PRMT5-MEP50 was diluted to 4.5 μM in 25 mM Bicine pH 7.6, 100 mM NaCl, 1 mM TCEP, and 0.05% Tween-20 and injected at 5...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataKd: 6nMAssay Description:Table A2: In vivo biotinylated PRMT5-MEP50 was diluted to 4.5 μM in 25 mM Bicine pH 7.6, 100 mM NaCl, 1 mM TCEP, and 0.05% Tween-20 and injected at 5...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataKd: 6nMAssay Description:Table A2: In vivo biotinylated PRMT5-MEP50 was diluted to 4.5 μM in 25 mM Bicine pH 7.6, 100 mM NaCl, 1 mM TCEP, and 0.05% Tween-20 and injected at 5...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 7nMAssay Description:Table A1: A recombinant human dual expressed Avi PRMT5/His-MEP50) protein (corresponding to amino acids for PRMT5 2-637, and 2-342 for MEP50 expresse...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 7nMAssay Description:Table A1: A recombinant human dual expressed Avi PRMT5/His-MEP50) protein (corresponding to amino acids for PRMT5 2-637, and 2-342 for MEP50 expresse...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 8nMAssay Description:Table A1: A recombinant human dual expressed Avi PRMT5/His-MEP50) protein (corresponding to amino acids for PRMT5 2-637, and 2-342 for MEP50 expresse...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 9nMAssay Description:Table A1: A recombinant human dual expressed Avi PRMT5/His-MEP50) protein (corresponding to amino acids for PRMT5 2-637, and 2-342 for MEP50 expresse...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataKd: 9nMAssay Description:Table A2: In vivo biotinylated PRMT5-MEP50 was diluted to 4.5 μM in 25 mM Bicine pH 7.6, 100 mM NaCl, 1 mM TCEP, and 0.05% Tween-20 and injected at 5...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataKd: 12nMAssay Description:Table A2: In vivo biotinylated PRMT5-MEP50 was diluted to 4.5 μM in 25 mM Bicine pH 7.6, 100 mM NaCl, 1 mM TCEP, and 0.05% Tween-20 and injected at 5...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataKd: 12nMAssay Description:Table A2: In vivo biotinylated PRMT5-MEP50 was diluted to 4.5 μM in 25 mM Bicine pH 7.6, 100 mM NaCl, 1 mM TCEP, and 0.05% Tween-20 and injected at 5...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 12.1nMAssay Description:Table B1: The assay uses purified human, PRMT5 enzyme to convert S-adenosyl-L-[methyl-3H]methionine plus histone H4 L-arginine to S-adenosyl-L-homocy...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 13nMAssay Description:Table A1: A recombinant human dual expressed Avi PRMT5/His-MEP50) protein (corresponding to amino acids for PRMT5 2-637, and 2-342 for MEP50 expresse...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataKd: 17nMAssay Description:Table A2: In vivo biotinylated PRMT5-MEP50 was diluted to 4.5 μM in 25 mM Bicine pH 7.6, 100 mM NaCl, 1 mM TCEP, and 0.05% Tween-20 and injected at 5...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 20.3nMAssay Description:Table B1: The assay uses purified human, PRMT5 enzyme to convert S-adenosyl-L-[methyl-3H]methionine plus histone H4 L-arginine to S-adenosyl-L-homocy...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 21nMAssay Description:Table A1: A recombinant human dual expressed Avi PRMT5/His-MEP50) protein (corresponding to amino acids for PRMT5 2-637, and 2-342 for MEP50 expresse...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataKd: 22nMAssay Description:Table A2: In vivo biotinylated PRMT5-MEP50 was diluted to 4.5 μM in 25 mM Bicine pH 7.6, 100 mM NaCl, 1 mM TCEP, and 0.05% Tween-20 and injected at 5...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 24nMAssay Description:Table A1: A recombinant human dual expressed Avi PRMT5/His-MEP50) protein (corresponding to amino acids for PRMT5 2-637, and 2-342 for MEP50 expresse...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 29nMAssay Description:Table A1: A recombinant human dual expressed Avi PRMT5/His-MEP50) protein (corresponding to amino acids for PRMT5 2-637, and 2-342 for MEP50 expresse...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataKd: 33nMAssay Description:Table A2: In vivo biotinylated PRMT5-MEP50 was diluted to 4.5 μM in 25 mM Bicine pH 7.6, 100 mM NaCl, 1 mM TCEP, and 0.05% Tween-20 and injected at 5...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 37nMAssay Description:Table A1: A recombinant human dual expressed Avi PRMT5/His-MEP50) protein (corresponding to amino acids for PRMT5 2-637, and 2-342 for MEP50 expresse...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataKd: 38nMAssay Description:Table A2: In vivo biotinylated PRMT5-MEP50 was diluted to 4.5 μM in 25 mM Bicine pH 7.6, 100 mM NaCl, 1 mM TCEP, and 0.05% Tween-20 and injected at 5...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataKd: 43nMAssay Description:Table A2: In vivo biotinylated PRMT5-MEP50 was diluted to 4.5 μM in 25 mM Bicine pH 7.6, 100 mM NaCl, 1 mM TCEP, and 0.05% Tween-20 and injected at 5...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 60.2nMAssay Description:Table B2: The assay uses recombinant full-length histone H2A as the PRMT5 substrate. Enzymatic transfer of the tritiated methyl group from S-adenosyl...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataKd: 66nMAssay Description:Table A2: In vivo biotinylated PRMT5-MEP50 was diluted to 4.5 μM in 25 mM Bicine pH 7.6, 100 mM NaCl, 1 mM TCEP, and 0.05% Tween-20 and injected at 5...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataKd: 72nMAssay Description:Table A2: In vivo biotinylated PRMT5-MEP50 was diluted to 4.5 μM in 25 mM Bicine pH 7.6, 100 mM NaCl, 1 mM TCEP, and 0.05% Tween-20 and injected at 5...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 73nMAssay Description:Table A1: A recombinant human dual expressed Avi PRMT5/His-MEP50) protein (corresponding to amino acids for PRMT5 2-637, and 2-342 for MEP50 expresse...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataKd: 80nMAssay Description:Table A2: In vivo biotinylated PRMT5-MEP50 was diluted to 4.5 μM in 25 mM Bicine pH 7.6, 100 mM NaCl, 1 mM TCEP, and 0.05% Tween-20 and injected at 5...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataKd: 81nMAssay Description:Table A2: In vivo biotinylated PRMT5-MEP50 was diluted to 4.5 μM in 25 mM Bicine pH 7.6, 100 mM NaCl, 1 mM TCEP, and 0.05% Tween-20 and injected at 5...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataKd: 94nMAssay Description:Table A2: In vivo biotinylated PRMT5-MEP50 was diluted to 4.5 μM in 25 mM Bicine pH 7.6, 100 mM NaCl, 1 mM TCEP, and 0.05% Tween-20 and injected at 5...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 102nMAssay Description:Table A1: A recombinant human dual expressed Avi PRMT5/His-MEP50) protein (corresponding to amino acids for PRMT5 2-637, and 2-342 for MEP50 expresse...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataKd: 105nMAssay Description:Table A2: In vivo biotinylated PRMT5-MEP50 was diluted to 4.5 μM in 25 mM Bicine pH 7.6, 100 mM NaCl, 1 mM TCEP, and 0.05% Tween-20 and injected at 5...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 123nMAssay Description:Table B2: The assay uses recombinant full-length histone H2A as the PRMT5 substrate. Enzymatic transfer of the tritiated methyl group from S-adenosyl...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 124nMAssay Description:Table A1: A recombinant human dual expressed Avi PRMT5/His-MEP50) protein (corresponding to amino acids for PRMT5 2-637, and 2-342 for MEP50 expresse...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataKd: 137nMAssay Description:Table A2: In vivo biotinylated PRMT5-MEP50 was diluted to 4.5 μM in 25 mM Bicine pH 7.6, 100 mM NaCl, 1 mM TCEP, and 0.05% Tween-20 and injected at 5...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataKd: 137nMAssay Description:Table A2: In vivo biotinylated PRMT5-MEP50 was diluted to 4.5 μM in 25 mM Bicine pH 7.6, 100 mM NaCl, 1 mM TCEP, and 0.05% Tween-20 and injected at 5...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 138nMAssay Description:Table A1: A recombinant human dual expressed Avi PRMT5/His-MEP50) protein (corresponding to amino acids for PRMT5 2-637, and 2-342 for MEP50 expresse...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 138nMAssay Description:Table B1: The assay uses purified human, PRMT5 enzyme to convert S-adenosyl-L-[methyl-3H]methionine plus histone H4 L-arginine to S-adenosyl-L-homocy...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataKd: 151nMAssay Description:Table A2: In vivo biotinylated PRMT5-MEP50 was diluted to 4.5 μM in 25 mM Bicine pH 7.6, 100 mM NaCl, 1 mM TCEP, and 0.05% Tween-20 and injected at 5...More data for this Ligand-Target Pair
TargetProtein arginine N-methyltransferase 5 (PRMT5) and Methylosome protein WDR77 (MEP-50)(Human)
Mirati Therapeutics
US Patent
Mirati Therapeutics
US Patent
Affinity DataIC50: 158nMAssay Description:Table A1: A recombinant human dual expressed Avi PRMT5/His-MEP50) protein (corresponding to amino acids for PRMT5 2-637, and 2-342 for MEP50 expresse...More data for this Ligand-Target Pair






















